Regulation of Akt mRNA and protein levels by glycogen synthase kinase-3β in adrenal chromaffin cells: Effects of LiCl and SB216763

European Journal of Pharmacology

Volumn 586, Issue 1-3, 2008, Pages 82-89

  Nemoto, Takayuki ^a   Kanai, Tasuku ^a   Yanagita, Toshihiko ^a   Satoh, Shinya ^a   Maruta, Toyoaki ^a   Yoshikawa, Norie ^a   Kobayashi, Hideyuki ^a   Wada, Akihiko ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Catenin; Adrenal chromaffin cell; Glycogen synthase kinase 3 ; LiCl; SB216763; Up and down regulation of Akt1

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; BETA CATENIN; BETA LACTONE; CALPASTATIN; GLYCOGEN SYNTHASE KINASE 3BETA; LACTACYSTIN; LEUPEPTIN; LITHIUM CHLORIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEASOME INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B BETA;

ANIMAL CELL; ARTICLE; CELL CULTURE; CHROMAFFIN CELL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; NONHUMAN; PRIORITY JOURNAL; RNA STABILITY; STEADY STATE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BETA CATENIN; BLOTTING, NORTHERN; BLOTTING, WESTERN; CATTLE; CELLS, CULTURED; CHROMAFFIN CELLS; GLYCOGEN SYNTHASE KINASE 3; INDOLES; LITHIUM CHLORIDE; MALEIMIDES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; ONCOGENE PROTEIN V-AKT; PHOSPHORYLATION; PROTEASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER;

EID: 43549123034     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.02.075     Document Type: Article

References (65)

1. Bao Z., Lim S., Liao W., Lin Y., Thiemermann C., Leung B.P., and Wong W.S.F. Glycogen synthase kinase-3β inhibition attenuates asthma in mice. Am. J. Respir. Crit. Care Med. 176 (2007) 431-438
2. Beaulieu J.-M., Sotnikova T.D., Yao W.-D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., and Caron M.G. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 5099-5104
3. Bernal-Mizrachi E., Fatrai S., Johnson J.D., Ohsugi M., Otani K., Han Z., Polonsky K.S., and Permutt M.A. Defective insulin secretion and increased susceptibility to experimental diabetes are induced by reduced Akt activity in pancreatic islet β cells. J. Clin. Invest. 114 (2004) 928-936
4. Brazil D.P., Yang Z.-Z., and Hemmings B.A. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem. Sci. 29 (2004) 233-242
5. Ca channels in developing parasympathetic neurons. J. Neurophysiol. 93 (2005) 1174-1182
6. Chalecka-Franaszek E., and Chuang D.-M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc. Natl. Acad. Sci. USA 96 (1999) 8745-8750
7. Clodfelder-Miller B., De Sarno P., Zmijewska A.A., Song L., and Jope R.S. Physiological and pathological changes in glucose regulate brain Akt and glycogen synthase kinase-3. J. Biol. Chem. 280 (2005) 39723-39731
8. Coghlan M.P., Culbert A.A., Cross D.A.E., Corcoran S.L., Yates J.W., Pearce N.J., Rausch O.L., Murphy G.J., Carter P.S., Cox L.R., Mills D., Brown M.J., Haigh D., Ward R.W., Smith D.G., Murray K.J., Reith A.D., and Holder J.C. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. 7 (2000) 793-803
9. Colin E., Régulier E., Perrin V., Dürr A., Brice A., Aebischer P., Déglon N., Humbert S., and Saudou F. Akt is altered in an animal model of Huntington's disease and in patients. Eur. J. Neurosci. 21 (2005) 1478-1488
10. Dihlmann S., Kloor M., Fallsehr C., and von Knebel Doeberitz M. Regulation of Aktl expression by beta-catenin/Tcf/Lef signaling in colorectal cancer cells. Carcinogenesis 26 (2005) l503-l1512
11. Dugo L., Collin M., Allen D.A., Murch O., Foster S.J., Yagoob M.M., and Thiemermann C. Insulin reduces the multiple organ injury and dysfunction caused by coadministration of lipopolysaccharide and peptidoglycan independently of blood glucose: role of glycogen synthase kinase-3β inhibition. Crit. Care Med. 34 (2006) 1489-1496
12. Easton R.M., Cho H., Roovers K., Shineman D.W., Mizrahi M., Forman M.S., Lee V.M.-Y., Szabolcs M., de Jong R., Oltersdorf T., Ludwig T., Efstratiadis A., and Birnbaum M.J. Role of Akt3/protein kinase Bγ in attainment of normal brain size. Mol. Cell. Biol. 25 (2005) 1869-1878
13. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., and Gogos J.A. Convergent evidence for impaired AKTl-GSK3β signaling in schizophrenia. Nat. Genet. 36 (2004) 131-137
14. Evans G.J.O., Barclay J.W., Prescott G.R., Jo S.-R., Burgoyne R.D., Birnbaum M.J., and Morgan A. Protein kinase B/Akt is a novel cysteine string protein kinase that regulates exocytosis release kinetics and quantal size. J. Biol. Chem. 281 (2006) 1564-1572
15. 129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression. J. Biol. Chem. 269 (1994) 32187-32193
16. Grimes C.A., and Jope R.S. CREB DNA binding activity is inhibited by glycogen synthase kinase-3β and facilitated by lithium. J. Neurochem. 78 (2001) 1219-1232
17. Gurvich N., and Klein P.S. Lithium and valproic acid: parallels and contrasts in diverse signaling contexts. Pharmacol. Ther. 96 (2002) 45-66
18. Hoeflich K.P., Luo J., Rubie E.A., Tsao M.-S., Jin O., and Woodgett J.R. Requirement of glycogen synthase kinase-3β in cell survival and NF-kB activation. Nature 406 (2000) 86-90
19. Hosoi T., Hyoda K., Okuma Y., Nomura Y., and Ozawa K. Akt up- and down-regulation in response to endoplasmic reticulum stress. Brain Res. 1152 (2007) 27-31
20. Humbert S., Bryson E.A., Cordelières F.P., Connors N.C., Datta S.R., Finkbeiner S., Greenberg M.E., and Saudou F. The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell 2 (2002) 831-837
21. Jope R.S. Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol. Sci. 24 (2003) 441-443
22. Jope R.S., and Johnson G.V.W. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 29 (2004) 95-102
23. Jope R.S., Yuskaitis C.J., and Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem. Res. 32 (2007) 577-595
24. Kaspar B.K., Lladó J., Sherkat N., Rothstein J.D., and Gage F.H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301 (2003) 839-842
25. Kim A.H., Yano H., Cho H., Meyer D., Monks B., Margolis B., Birnbaum M.J., and Chao M.V. Aktl regulates a JNK scaffold during excitotoxic apoptosis. Neuron 35 (2002) 697-709
26. Klein P.S., and Melton D.A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 8455-8459
27. Lee Y.-I., Seo M., Kim Y., Kim S.-Y., Kang U.G., Kim Y.-S., and Juhnn Y.-S. Membrane depolarization induces the undulating phosphorylation/dephosphorylation of glycogen synthase kinase 3β, and this dephosphorylation involves protein phosphatases 2A and 2B in SH-SY5Y human neuroblastoma cells. J. Biol. Chem. 280 (2005) 22044-22052
28. Léger B., Vergani L., Sorarù G., Hespel P., Derave W., Gobelet C., D'Ascenzio C., Angelini C., and Russell A.P. Human skeletal muscle atrophy in amyotrophic lateral sclerosis reveals a reduction in Akt and an increase in atrogin-1. FASEB J. 20 (2006) 538-585
29. Manning B.D. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J. Cell Biol. 167 (2004) 399-403
30. Manning B.D., and Cantley L.C. Akt/PKB signaling: navigating downstream. Cell 129 (2007) 1261-1274
31. Markus A., Zhong J., and Snider W.D. Raf and Akt mediate distinct aspects of sensory axon growth. Neuron 35 (2002) 65-76
32. Martelli A.M., Faenza I., Billi A.M., Manzoli L., Evangelisti C., Falà F., and Cocco L. Intranuclear 3′-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis?. Cell. Signal. 18 (2006) 1101-1107
33. Meijer L., Flajolet M., and Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol. Sci. 25 (2004) 471-480
34. Misra U.K., and Pizzo S.V. Upregulation of Akt1 protein expression in forskolin-stimulated macrophages: evidence from ChIP analysis that CREB binds to and activates the Akt1 promoter. J. Cell. Biochem. 100 (2007) 1022-1033
35. Nagano I., Ilieva H., Shiote M., Murakami T., Yokoyama M., Shoji M., and Abe K. Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of amyotrophic lateral sclerosis. J. Neurol. Sci. 235 (2005) 61-68
36. Nemoto T., Yokoo H., Satoh S., Yanagita T., Sugano T., Yoshikawa N., Maruta T., Kobayashi H., and Wada A. Constitutive activity of glycogen synthase kinase-3β: positive regulation of steady-state levels of insulin receptor substrates-1 and -2 in adrenal chromaffin cells. Brain Res. 1110 (2006) 1-12
37. O'Brien W.T., Harper A.D., Jové F., Woodgett J.R., Maretto S., Piccolo S., and Klein P.S. Glycogen synthase kinase-3β haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci. 24 (2004) 6791-6798
38. Ogata T., Iijima S., Hoshikawa S., Miura T., Yamamoto S., Oda H., Nakamura K., and Tanaka S. Opposing extracellular signal-regulated kinase and Akt pathways control Schwann cell myelination. J. Neurosci. 24 (2004) 6724-6732
39. Parcellier A., Tintignac L.A., Zhuravleva E., and Hemmings B.A. PKB and the mitochondria: AKTing on apoptosis. Cell. Signal. 20 (2007) 21-31
40. Park S., Kim D., Kaneko S., Szewczyk K.M., Nicosia S.V., Yu H., Jove R., and Cheng J.Q. Molecular cloning and characterization of the human Akt1 promoter uncovers its up-regulation by the Src/Stat3 pathway. J. Biol. Chem. 280 (2005) 38932-38941
41. Pezet S., Spyropoulos A., Williams R.J., and McMahon S.B. Activity-dependent phosphorylation of Akt/PKB in adult DRG neurons. Eur. J. Neurosci. 21 (2005) 1785-1797
42. 260 by Akt inhibits polyQ-huntingtin-induced toxicity by rescuing proteasome impairment. J. Biol. Chem. 280 (2005) 22021-22028
43. Roh M.-S., Kang U.G., Shin S.Y., Lee Y.H., Jung H.Y., Juhnn Y.-S., and Kim Y.S. Biphasic changes in the Ser-9 phosphorylation of glycogen synthase kinase-3β after electroconvulsive shock in the rat brain. Prog. Neuropsychopharmacol Biol Psychiatry 27 (2003) 1-5
44. Russo S.J., Bolanos C.A., Theobald D.E., DeCarolis N.A., Renthal W., Kumar A., Winstanley C.A., Renthal N.E., Wiley M.D., Self D.W., Russell D.S., Neve R.L., Eisch A.J., and Nestler E.J. IRS2-Akt pathway in midbrain dopamine neurons regulates behavioral and cellular responses to opiates. Nat. Neurosci 10 (2007) 93-99
45. Sasaki T., Han F., Shioda N., Moriguchi S., Kasahara J., Ishiguro K., and Fukunaga K. Lithium-induced activation of Akt and CaM kinase II contributes to its neuroprotective action in a rat microsphere embolism model. Brain Res. 1108 (2006) 98-106
46. Shiraishi S., Shibuya I., Uezono Y., Yokoo H., Toyohira Y., Yamamoto R., Yanagita T., Kobayashi H., and Wada A. Heterogeneous increases of cytoplasmic calcium: distinct effects on down-regulation of cell surface sodium channels and sodium channel subunit mRNA levels. Br. J. Pharmacol. 132 (2001) 1455-1466
47. Song G., Ouyang G., and Bao S. The activation of Akt/PKB signaling pathway and cell survival. J. Cell. Mol. Med. 9 (2005) 59-71
48. Stambolic V., and Woodgett J.R. Functional distinctions of protein kinase B/Akt isoforms defined by their influence on cell migration. Trends Cell Biol. 16 (2006) 461-466
49. Sugano T., Yanagita T., Yokoo H., Satoh S., Kobayashi H., and Wada A. Enhancement of insulin-induced PI3K/Akt/GSK-3β and ERK signalings by neuronal nicotinic receptor/PKC-α/ERK pathway: up-regulation of IRS-1/-2 mRNA and protein in adrenal chromaffin cells. J. Neurochem. 98 (2006) 20-33
50. Sun R., Yan J., and Willis W.D. Activation of protein kinase B/Akt in the periphery contributes to pain behavior induced by capsaicin in rats. Neuroscience 144 (2007) 286-294
51. Takada Y., Fang X., Jamaluddin M.S., Boyd D.D., and Aggarwal B.B. Genetic deletion of glycogen synthase kinase-3β abrogates activation of IkBα kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J. Biol. Chem. 279 (2004) 39541-39554
52. Takada-Takatori Y., Kume T., Sugimoto M., Katsuki H., Sugimoto H., and Akaike A. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology 51 (2006) 474-486
53. Takai N., Nakanishi H., Tanabe K., Nishioku T., Sugiyama T., Fujiwara M., and Yamamoto K. Involvement of caspase-like proteinases in apoptosis of neuronal PCl2 cells and primary cultured microglia induced by 6-hydroxydopamine. J. Neurosci. Res. 54 (1998) 214-222
54. Wada A., Yokoo H., Yanagita T., and Kobayashi H. New twist on neuronal insulin receptor signaling in health, disease, and therapeutics. J. Pharmacol. Sci. 99 (2005) 128-143
55. Wada A., Yokoo H., Yanagita T., and Kobayashi H. Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases. J. Pharmacol. Sci. 99 (2005) 307-321
56. Wang Q., Liu L., Pei L., Ju W., Ahmadian G., Lu J., Wang Y., Liu F., and Wang Y.T. Control of synaptic strength, a novel function of Akt. Neuron 38 (2003) 915-928
57. Warita H., Manabe Y., Murakami T., Shiro Y., Nagano I., and Abe K. Early decrease of survival signal-related proteins in spinal motor neurons of presymptomatic transgenic mice with a mutant SODl gene. Apoptosis 6 (2001) 345-352
58. Weihl C.C., Ghadge G.D., Kennedy S.G., Hay N., Miller R.J., and Roos R.P. Mutant presenilin-1 induces apoptosis and downregulates Akt/PKB. J. Neurosci. 19 (1999) 5360-5369
59. Xu J., Liu D., and Songyang Z. The role of Asp-462 in regulating Akt activity. J. Biol. Chem. 277 (2002) 35561-35566
60. Yamamoto R., Yanagita T., Kobayashi H., Yuhi T., Yokoo H., and Wada A. Up-regulation of functional voltage-dependent sodium channels by insulin in cultured bovine adrenal chromaffin cells. J. Neurochem. 67 (1996) 1401-1408
61. Yamamoto R., Yanagita T., Kobayashi H., Yokoo H., and Wada A. Up-regulation of sodium channel subunit mRNAs and their cell surface expression by antiepileptic valproic acid: activation of calcium channel and catecholamine secretion in adrenal chromaffin cells. J. Neurochem. 68 (1997) 1655-1662
62. Yan D., Guo L., and Wang Y. Requirement of dendritic Akt degradation by the ubiquitin-proteasome system for neuronal polarity. J. Cell Biol. 174 (2006) 415-424
63. + channel expression. J. Pharmacol. Sci. 103 Suppl. I (2007) 101P
64. Yoeli-Lerner M., and Toker A. Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle 5 (2006) 603-605
65. Yokoo H., Nemoto T., Yanagita T., Satoh S., Yoshikawa N., Maruta T., and Wada A. Glycogen synthase kinase-3β: homologous regulation of cell surface insulin receptor level via controlling insulin receptor mRNA stability in adrenal chromaffin cells. J. Neurochem. 103 (2007) 1883-1896